WALDEN NURS 6521
ADVANCED PHARMACOLOGY FINAL EXAM
2026/2027 Edition | 100 Questions
100% Verified | Latest Update | Questions & Answers | Graded A+
Based on: Lehne's Pharmacology for Nursing Care, Rosenthal & Burchum's
Pharmacotherapeutics
for Advanced Practice, ACC/AHA, ADA, IDSA, APA, CDC, GOLD Guidelines
Passing Score: 75-80% | Testing Time: 120-150 Minutes | NGN-Aligned Format
,Table of Contents
Section 1: Pharmacokinetics & Pharmacodynamics Principles (Questions 1-6)
Section 2: Medication Administration & Safety Protocols (Questions 7-11)
Section 3: Cardiovascular Pharmacology (Questions 12-19)
Section 4: Respiratory Pharmacology (Questions 20-25)
Section 5: Endocrine Pharmacology (Questions 26-33)
Section 6: CNS & Psychiatric Pharmacology (Questions 34-42)
Section 7: Pain Management & Opioid Stewardship (Questions 43-49)
Section 8: Anti-Infective Pharmacology (Questions 50-58)
Section 9: Gastrointestinal Pharmacology (Questions 59-63)
Section 10: Hematologic & Oncologic Pharmacology (Questions 64-70)
Section 11: Special Populations Pharmacology (Questions 71-76)
Section 12: Drug Interactions & Adverse Effect Recognition (Questions 77-82)
Section 13: Patient Education & Health Literacy (Questions 83-86)
Section 14: Prescriptive Authority & Regulatory Compliance (Questions 87-90)
Section 15: Evidence-Based Prescribing & Scenario-Based Clinical Decision-Making (Questions
91-100)
,Section 1: Pharmacokinetics & Pharmacodynamics Principles
Question 1. A nurse practitioner prescribes a medication with a high first-pass
effect. Which route of administration would bypass the hepatic first-pass
metabolism and achieve the highest bioavailability?
A. Oral
B. Sublingual
C. Intramuscular
D. Rectal
Rationale: The first-pass effect refers to the initial metabolism of a drug by the liver before it
reaches systemic circulation. Drugs administered orally are absorbed through the GI tract and
enter the portal vein, which carries them directly to the liver where significant metabolism may
occur. Sublingual administration allows the drug to be absorbed through the highly
vascularized sublingual mucosa directly into the systemic circulation via the superior vena
cava, completely bypassing the portal circulation and hepatic first-pass metabolism.
Intramuscular and rectal routes also partially bypass first-pass metabolism but not as
completely as sublingual. Sublingual nitroglycerin is a classic example of a drug with high first-
pass metabolism that requires sublingual administration for therapeutic effectiveness.
Question 2. A patient with chronic liver disease is prescribed a medication that is
highly protein-bound (98%). Which pharmacokinetic principle should the nurse
practitioner consider?
A. Liver disease will increase the free (active) drug fraction, potentially increasing
drug effects and toxicity risk
B. Protein binding is unaffected by liver disease since albumin is produced in the kidneys
C. Highly protein-bound drugs are always safer because only the unbound fraction is active
D. Liver disease decreases the free drug fraction, requiring higher doses
Rationale: Highly protein-bound drugs (>90%) bind primarily to albumin (for acidic drugs)
or alpha-1 acid glycoprotein (for basic drugs). Only the unbound (free) fraction is
pharmacologically active and available for metabolism and excretion. In chronic liver disease,
hepatic synthesis of albumin is impaired, leading to hypoalbuminemia. With less albumin
available, a greater proportion of the drug remains unbound (free), increasing the active drug
concentration and potentially leading to enhanced pharmacological effects and toxicity at
standard doses. The nurse practitioner should monitor for signs of drug toxicity and consider
dose reduction for highly protein-bound drugs in patients with liver disease and
hypoalbuminemia. Common highly protein-bound drugs include warfarin, phenytoin, and
diazepam.
Question 3. A medication has a half-life of 12 hours. How long will it take to reach
approximately steady-state concentration with repeated dosing?
A. 12 hours
B. 24 hours
C. 48-60 hours (approximately 4-5 half-lives)
D. 120 hours
Rationale: Steady-state concentration is achieved when the rate of drug administration equals
the rate of drug elimination. It takes approximately 4-5 half-lives to reach approximately 94-
, 97% of steady-state. For a drug with a 12-hour half-life: 1 half-life = 12 hours (50%), 2 half-lives
= 24 hours (75%), 3 half-lives = 36 hours (87.5%), 4 half-lives = 48 hours (93.75%), 5 half-lives =
60 hours (96.9%). Therefore, steady state is reached in approximately 48-60 hours. A loading
dose can be administered to achieve therapeutic levels more rapidly, calculated as
approximately twice the maintenance dose for drugs with first-order kinetics. This principle is
essential for drugs requiring therapeutic monitoring such as digoxin, phenytoin, and
aminoglycosides.
Question 4. A drug with a narrow therapeutic index has which of the following
characteristics?
A. A wide margin between the toxic dose and the effective dose
B. A small difference between the minimum effective concentration and the
minimum toxic concentration, requiring close therapeutic drug monitoring
C. No risk of toxicity at any dose
D. Rapid elimination that prevents drug accumulation
Rationale: The therapeutic index (TI) is the ratio of the toxic dose (TD50) to the effective dose
(ED50). A narrow therapeutic index means there is a small margin between the dose that
produces the desired therapeutic effect and the dose that causes toxicity. Drugs with a narrow
TI require careful dosing, therapeutic drug monitoring (TDM), and close patient observation.
Classic examples include digoxin (therapeutic range 0.5-2.0 ng/mL), warfarin (target INR 2.0-
3.0), lithium (0.6-1.2 mEq/L), phenytoin (10-20 mcg/mL), theophylline (10-20 mcg/mL), and
aminoglycosides. Factors that increase toxicity risk include renal or hepatic impairment, drug
interactions, and individual genetic variations in drug metabolism (pharmacogenomics).
Question 5. A patient taking a CYP450 3A4 inhibitor (ketoconazole) is started on a
new medication metabolized primarily by CYP3A4. What effect should the nurse
practitioner anticipate?
A. Increased metabolism of the new drug, requiring a higher dose
B. Decreased metabolism of the new drug, increasing its plasma concentration
and potential for toxicity
C. No effect, as CYP enzymes do not interact with antifungal medications
D. Induction of alternative metabolic pathways only
Rationale: CYP450 enzymes (particularly CYP3A4, CYP2D6, CYP2C9, CYP2C19) are the
primary drug-metabolizing enzymes in the liver. Ketoconazole is a potent CYP3A4 inhibitor that
blocks the enzymatic activity, reducing the metabolism of concurrently administered drugs that
are CYP3A4 substrates. This inhibition leads to increased plasma concentrations of the affected
drug, potentially increasing both therapeutic effects and the risk of toxicity. The nurse
practitioner should reduce the dose of the CYP3A4 substrate drug or select an alternative agent.
Common CYP3A4 inhibitors include azole antifungals (ketoconazole, itraconazole), macrolide
antibiotics (erythromycin, clarithromycin), grapefruit juice, HIV protease inhibitors, and
amiodarone. Common CYP3A4 inducers include rifampin, carbamazepine, phenytoin, and St.
John's wort (which have the opposite effect).
Question 6. A drug acts as a competitive antagonist at its receptor. Which
pharmacodynamic principle describes the effect of increasing the agonist
concentration in the presence of this antagonist?
A. The agonist effect cannot be restored at any concentration
ADVANCED PHARMACOLOGY FINAL EXAM
2026/2027 Edition | 100 Questions
100% Verified | Latest Update | Questions & Answers | Graded A+
Based on: Lehne's Pharmacology for Nursing Care, Rosenthal & Burchum's
Pharmacotherapeutics
for Advanced Practice, ACC/AHA, ADA, IDSA, APA, CDC, GOLD Guidelines
Passing Score: 75-80% | Testing Time: 120-150 Minutes | NGN-Aligned Format
,Table of Contents
Section 1: Pharmacokinetics & Pharmacodynamics Principles (Questions 1-6)
Section 2: Medication Administration & Safety Protocols (Questions 7-11)
Section 3: Cardiovascular Pharmacology (Questions 12-19)
Section 4: Respiratory Pharmacology (Questions 20-25)
Section 5: Endocrine Pharmacology (Questions 26-33)
Section 6: CNS & Psychiatric Pharmacology (Questions 34-42)
Section 7: Pain Management & Opioid Stewardship (Questions 43-49)
Section 8: Anti-Infective Pharmacology (Questions 50-58)
Section 9: Gastrointestinal Pharmacology (Questions 59-63)
Section 10: Hematologic & Oncologic Pharmacology (Questions 64-70)
Section 11: Special Populations Pharmacology (Questions 71-76)
Section 12: Drug Interactions & Adverse Effect Recognition (Questions 77-82)
Section 13: Patient Education & Health Literacy (Questions 83-86)
Section 14: Prescriptive Authority & Regulatory Compliance (Questions 87-90)
Section 15: Evidence-Based Prescribing & Scenario-Based Clinical Decision-Making (Questions
91-100)
,Section 1: Pharmacokinetics & Pharmacodynamics Principles
Question 1. A nurse practitioner prescribes a medication with a high first-pass
effect. Which route of administration would bypass the hepatic first-pass
metabolism and achieve the highest bioavailability?
A. Oral
B. Sublingual
C. Intramuscular
D. Rectal
Rationale: The first-pass effect refers to the initial metabolism of a drug by the liver before it
reaches systemic circulation. Drugs administered orally are absorbed through the GI tract and
enter the portal vein, which carries them directly to the liver where significant metabolism may
occur. Sublingual administration allows the drug to be absorbed through the highly
vascularized sublingual mucosa directly into the systemic circulation via the superior vena
cava, completely bypassing the portal circulation and hepatic first-pass metabolism.
Intramuscular and rectal routes also partially bypass first-pass metabolism but not as
completely as sublingual. Sublingual nitroglycerin is a classic example of a drug with high first-
pass metabolism that requires sublingual administration for therapeutic effectiveness.
Question 2. A patient with chronic liver disease is prescribed a medication that is
highly protein-bound (98%). Which pharmacokinetic principle should the nurse
practitioner consider?
A. Liver disease will increase the free (active) drug fraction, potentially increasing
drug effects and toxicity risk
B. Protein binding is unaffected by liver disease since albumin is produced in the kidneys
C. Highly protein-bound drugs are always safer because only the unbound fraction is active
D. Liver disease decreases the free drug fraction, requiring higher doses
Rationale: Highly protein-bound drugs (>90%) bind primarily to albumin (for acidic drugs)
or alpha-1 acid glycoprotein (for basic drugs). Only the unbound (free) fraction is
pharmacologically active and available for metabolism and excretion. In chronic liver disease,
hepatic synthesis of albumin is impaired, leading to hypoalbuminemia. With less albumin
available, a greater proportion of the drug remains unbound (free), increasing the active drug
concentration and potentially leading to enhanced pharmacological effects and toxicity at
standard doses. The nurse practitioner should monitor for signs of drug toxicity and consider
dose reduction for highly protein-bound drugs in patients with liver disease and
hypoalbuminemia. Common highly protein-bound drugs include warfarin, phenytoin, and
diazepam.
Question 3. A medication has a half-life of 12 hours. How long will it take to reach
approximately steady-state concentration with repeated dosing?
A. 12 hours
B. 24 hours
C. 48-60 hours (approximately 4-5 half-lives)
D. 120 hours
Rationale: Steady-state concentration is achieved when the rate of drug administration equals
the rate of drug elimination. It takes approximately 4-5 half-lives to reach approximately 94-
, 97% of steady-state. For a drug with a 12-hour half-life: 1 half-life = 12 hours (50%), 2 half-lives
= 24 hours (75%), 3 half-lives = 36 hours (87.5%), 4 half-lives = 48 hours (93.75%), 5 half-lives =
60 hours (96.9%). Therefore, steady state is reached in approximately 48-60 hours. A loading
dose can be administered to achieve therapeutic levels more rapidly, calculated as
approximately twice the maintenance dose for drugs with first-order kinetics. This principle is
essential for drugs requiring therapeutic monitoring such as digoxin, phenytoin, and
aminoglycosides.
Question 4. A drug with a narrow therapeutic index has which of the following
characteristics?
A. A wide margin between the toxic dose and the effective dose
B. A small difference between the minimum effective concentration and the
minimum toxic concentration, requiring close therapeutic drug monitoring
C. No risk of toxicity at any dose
D. Rapid elimination that prevents drug accumulation
Rationale: The therapeutic index (TI) is the ratio of the toxic dose (TD50) to the effective dose
(ED50). A narrow therapeutic index means there is a small margin between the dose that
produces the desired therapeutic effect and the dose that causes toxicity. Drugs with a narrow
TI require careful dosing, therapeutic drug monitoring (TDM), and close patient observation.
Classic examples include digoxin (therapeutic range 0.5-2.0 ng/mL), warfarin (target INR 2.0-
3.0), lithium (0.6-1.2 mEq/L), phenytoin (10-20 mcg/mL), theophylline (10-20 mcg/mL), and
aminoglycosides. Factors that increase toxicity risk include renal or hepatic impairment, drug
interactions, and individual genetic variations in drug metabolism (pharmacogenomics).
Question 5. A patient taking a CYP450 3A4 inhibitor (ketoconazole) is started on a
new medication metabolized primarily by CYP3A4. What effect should the nurse
practitioner anticipate?
A. Increased metabolism of the new drug, requiring a higher dose
B. Decreased metabolism of the new drug, increasing its plasma concentration
and potential for toxicity
C. No effect, as CYP enzymes do not interact with antifungal medications
D. Induction of alternative metabolic pathways only
Rationale: CYP450 enzymes (particularly CYP3A4, CYP2D6, CYP2C9, CYP2C19) are the
primary drug-metabolizing enzymes in the liver. Ketoconazole is a potent CYP3A4 inhibitor that
blocks the enzymatic activity, reducing the metabolism of concurrently administered drugs that
are CYP3A4 substrates. This inhibition leads to increased plasma concentrations of the affected
drug, potentially increasing both therapeutic effects and the risk of toxicity. The nurse
practitioner should reduce the dose of the CYP3A4 substrate drug or select an alternative agent.
Common CYP3A4 inhibitors include azole antifungals (ketoconazole, itraconazole), macrolide
antibiotics (erythromycin, clarithromycin), grapefruit juice, HIV protease inhibitors, and
amiodarone. Common CYP3A4 inducers include rifampin, carbamazepine, phenytoin, and St.
John's wort (which have the opposite effect).
Question 6. A drug acts as a competitive antagonist at its receptor. Which
pharmacodynamic principle describes the effect of increasing the agonist
concentration in the presence of this antagonist?
A. The agonist effect cannot be restored at any concentration
